Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders [Yahoo! Finance]
Neuphoria Therapeutics Inc. (NEUP)
Company Research
Source: Yahoo! Finance
/PRNewswire/ -- Lynx1 Master Fund LP (together with its affiliates, "Lynx1"), the beneficial owner of 875,328 shares of common stock, par value $0.00001 per share ("Common Stock"), of Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria" or the "Company"), today sent an open letter to the shareholders of Neuphoria.
Show less
Read more
Impact Snapshot
Event Time:
NEUP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEUP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEUP alerts
High impacting Neuphoria Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
NEUP
News
- Neuphoria Therapeutics (NASDAQ:NEUP) had its price target lowered by analysts at HC Wainwright from $21.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and PremiumGlobeNewswire
- Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions [Yahoo! Finance]Yahoo! Finance
- Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 FictionsGlobeNewswire
- Neuphoria Therapeutics Inc. Sends Letter to StockholdersGlobeNewswire